CEO bullish on drug for rare disease despite concerns
December 01, 2015 at 13:14 PM EST
BioMarin Pharmaceuticals' CEO is still optimistic about FDA approval of its Duchenne muscular dystrophy drug, drisapersen, despite FDA concerns.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.